CSI Market
Sign In | Register

Protalix Biotherapeutics inc (PLX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PLX Annual Cash Flow →
The data below summarizes Protalix Biotherapeutics inc's cash flow activity from Mar 31 2025 to Mar 31 2026, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income18.32
Depreciation & amortization0.40
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4.75
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.54
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.16
Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement-
Gain Loss On Conversion Of Convertible Notes-
Income Loss On Conversion Of Convertible Notes-
Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes-
Gain Loss On Debt Conversion-
Change In Operating Lease Right Of Use Assets0.06
Income taxes0.07
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable6.41
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.82
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities22.03
Investing Activities
Capital Expenditures-0.76
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase Decrease In Restricted Deposit-0.01
Increase (Decrease) of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-0.01
Other Net5.00
Discontinued operations0.00
Net Cash Flow from Investing Activities4.22
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.57
Proceeds From Issuance Of Common Stock Net Of Expenses-
Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost-
Proceeds From Issuance Of Common Stock And Warrants Net-
Capital Expenditures Incurred But Not Yet Paid0.29
Right Of Use Asset Obtained In Exchange For Operating Lease Liability0.28
Debt Conversion Converted Instrument Amount-
Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of Related Funds-
Proceeds From Warrants And Stock Option Exercises0.15
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.15
Effect of exchange rate on cash flow-0.08
Discontinued operations0.00
Free Cash Flow21.26
Total Cash Flow26.32
4 historic quarters locked

Sign in to unlock the full Protalix Biotherapeutics inc cash flow history.

Sign In Create Free Account

About Protalix Biotherapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-094444

Figures are derived from filed reports and may be restated. Historical data is subject to revision.